{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T11:23:50Z","timestamp":1780399430580,"version":"3.54.1"},"reference-count":66,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T00:00:00Z","timestamp":1614038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:p>Malignant mesothelioma is an aggressive cancer with a poor prognosis and limited treatment options. For many years, the only US Food and Drug Administration\u2010approved first\u2010line treatment for unresectable mesothelioma was pemetrexed plus cisplatin. However, the recent approval of nivolumab plus ipilimumab as frontline treatment for patients with pleural mesothelioma marks a significant milestone for the treatment of this disease. In this review, the authors describe recent advances in therapeutic strategies for the treatment of patients with advanced, unresectable mesothelioma, highlighting the emerging use of immunotherapy and mesothelin\u2010targeted therapies for the management of malignant mesothelioma.<\/jats:p>","DOI":"10.1002\/cncr.33433","type":"journal-article","created":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T09:13:44Z","timestamp":1614071624000},"page":"1010-1020","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Malignant mesothelioma: Advances in immune checkpoint inhibitor and mesothelin\u2010targeted therapies"],"prefix":"10.1002","volume":"127","author":[{"given":"Zishuo I.","family":"Hu","sequence":"first","affiliation":[{"name":"Thoracic and GI Malignancies Branch Center for Cancer Research National Cancer Institute National Institutes of Health Bethesda Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azam","family":"Ghafoor","sequence":"additional","affiliation":[{"name":"Thoracic and GI Malignancies Branch Center for Cancer Research National Cancer Institute National Institutes of Health Bethesda Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjistha","family":"Sengupta","sequence":"additional","affiliation":[{"name":"Thoracic and GI Malignancies Branch Center for Cancer Research National Cancer Institute National Institutes of Health Bethesda Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4012-3633","authenticated-orcid":false,"given":"Raffit","family":"Hassan","sequence":"additional","affiliation":[{"name":"Thoracic and GI Malignancies Branch Center for Cancer Research National Cancer Institute National Institutes of Health Bethesda Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,2,23]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/CEJ.0b013e3282f0c0a2"},{"key":"e_1_2_8_3_1","volume-title":"SEER Cancer Statistics Review, 1975\u20102016","author":"Howlader N","year":"2017"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.15512.2"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6608a3"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2015.01.043"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2019.12.15"},{"key":"e_1_2_8_8_1","first-page":"566","article-title":"The mortality of amphibole miners in South Africa, 1946\u201080","volume":"49","author":"Sluis\u2010Cremer GK","year":"1992","journal-title":"Br J Ind Med"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-017-0929-4"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.656"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji278"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19950801)76:3<437::AID-CNCR2820760314>3.0.CO;2-A"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.855"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1194472"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2013.04.012"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.912"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy171"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.910"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgu227"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-5002(02)00180-0"},{"key":"e_1_2_8_21_1","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1158\/1078-0432.982.11.3","article-title":"Pemetrexed in malignant pleural mesothelioma","volume":"11","author":"Hazarika M","year":"2005","journal-title":"Clin Cancer Res"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.136"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00343"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30100-1"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.25"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990415)85:8<1740::AID-CNCR14>3.0.CO;2-9"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19970515)79:10<1897::AID-CNCR9>3.0.CO;2-D"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a058846"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2008.04.001"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01238-6"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.06.122"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000239"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30169-9"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.8565"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.05.038"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0103"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.5428"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70381-4"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(15)00092-2"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30446-1"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30151-6"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30420-X"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30765-4"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.08.004"},{"key":"e_1_2_8_45_1","unstructured":"US Food and Drug Administration (FDA).FDA approves nivolumab and ipilimumab for unresectable malignant pleural mesothelioma. Accessed October 20 2020.https:\/\/www.fda.gov\/drugs\/drug\u2010approvals\u2010and\u2010databases\/fda\u2010approves\u2010nivolumab\u2010and\u2010ipilimumab\u2010unresectable\u2010malignant\u2010pleural\u2010mesothelioma"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.08.276"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.9003"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.009"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-018-2602-y"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1703945"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS8581"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.08.1620"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-0337"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2614"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.3672"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-4658.2011.08182.x"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33145"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz7252"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.09.328"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02085"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3476"},{"key":"e_1_2_8_62_1","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1158\/1538-7445.AM2018-1781","article-title":"Abstract 1781: HPN536, a T cell\u2010engaging, mesothelin\/CD3\u2010specific TriTAC for the treatment of solid tumors","volume":"78","author":"Austin R","year":"2018","journal-title":"Cancer Res"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0170"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.07.015"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.2511"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10097-0"},{"key":"e_1_2_8_67_1","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1158\/1538-7445.AM2019-2307","article-title":"Abstract 2307: preclinical evaluation of TC\u2010210, a mesothelin\u2010specific T cell receptor (TCR) fusion construct (TRuC\u2122) T cells for the treatment of solid tumors","volume":"79","author":"Ding J","year":"2019","journal-title":"Cancer Res"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.33433","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.33433","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.33433","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T14:19:40Z","timestamp":1760278780000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.33433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,23]]},"references-count":66,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10.1002\/cncr.33433"],"URL":"https:\/\/doi.org\/10.1002\/cncr.33433","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,23]]},"assertion":[{"value":"2020-10-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}